Fundraising Fox
allumbra
Techstars '26Broomfield, US · Founded 2022 · 3 employees on LinkedIn · 1 known investors
Find your way into allumbra
Sign up to see every warm intro you have to allumbra
- Paths you didn't know you had: your email and LinkedIn already hold routes to the allumbra team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Allumbra combines quantum sensing technology with AI to analyze blood samples for early cancer detection. The company develops liquid biopsy tests that identify molecular signals of cancer before tumors become visible.
Also known as Allumbra
Founders & leadership
allumbra was founded in 2022 by Maria Navas-Moreno and Randy Carney.
Investors · 1
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · Not right? Tell us
Company profile
researched Sep 2026Allumbra is a diagnostics company developing a liquid biopsy platform that pairs a quantum/photonic sensing instrument with machine learning to extract molecular information from blood samples. The company's stated premise is that cancer leaves a molecular trace in circulation before a tumor becomes visible, and that this signal can be read directly from blood to produce tests that detect cancer earlier.
An initial application is a blood test for oncologists and cancer centers that uses photonics and AI to detect early cancer recurrence in head and neck cancer survivors, targeting the need for accurate and affordable post-treatment monitoring. The company's published science centers on Raman spectroscopy of blood, saliva and extracellular vesicles combined with machine learning, including work on fused Raman spectroscopic analysis of blood and saliva for head and neck cancer diagnostics (Scientific Reports, 2022), label-free Raman spectroscopy of extracellular vesicles for early-stage liquid biopsy cancer detection (AACR Annual Meeting 2024), and self-supervised learning toward a generalized model for Raman spectroscopy-based liquid biopsy cancer screening (Conference on Liquid Biopsy 2024).
Founding story
Allumbra was founded by scientists working from the conviction that cancer leaves a molecular trace before a tumor is visible, and they built an instrument intended to read that trace. Maria Navas-Moreno, PhD serves as CEO and co-founder and Randy Carney, PhD as CSO and co-founder.
Latest developments
In March 2026, Allumbra was announced as part of the Techstars AI Health Baltimore Spring 2026 accelerator class, a three-month program including mentorship and a capital investment. The company is also listed among partnering companies for the BIO International Convention.
▸Full profile — market position, technology, go-to-market
Market position
Positioned in liquid biopsy diagnostics, addressing recurrence monitoring for head and neck cancer survivors, a segment the company describes as having limited existing options for accurate and affordable monitoring.
Technology
The platform combines a quantum sensing/photonics instrument with AI to read molecular signals in blood. Associated peer-reviewed and conference work describes Raman spectroscopic analysis of blood and saliva for head and neck cancer diagnostics, label-free Raman spectroscopy of extracellular vesicles for early-stage liquid biopsy cancer detection, and self-supervised machine learning aimed at a generalized Raman spectroscopy-based liquid biopsy model for cancer screening.
Go-to-market
The company engages clinical sites, research collaborators and strategic partners through dedicated partnership and press channels, and publishes its science at oncology and liquid biopsy conferences. It provides quarterly email updates to investors and partners.
Oncologists and cancer centers monitoring head and neck cancer survivors for recurrence; the company also states it works with clinical sites, research collaborators and strategic partners.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Related companies · 3
Companies working in the same space as allumbra.
Timeline · 1
launches, deals, and filingsAllumbra was named among the startups joining the Techstars AI Health Baltimore program in the Spring 2026 accelerator class, a three-month program that includes mentorship and a strategic capital investment.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- allumbraallumbra.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does allumbra do?
- Allumbra develops a photonics- and AI-based liquid biopsy blood test for earlier cancer detection and recurrence monitoring.
- Who founded allumbra?
- allumbra was founded by Maria Navas-Moreno, Randy Carney in 2022.
- Who are allumbra's investors?
- allumbra's investors include Techstars.
- Where is allumbra headquartered?
- allumbra is headquartered in Broomfield, US.